uploads/2017/04/Graph-3-9-1.png

Humira Witnessed Solid Demand Trends in 1Q17

By

Updated

Humira growth trends

Despite competition from multiple drugs such as Amgen’s (AMGN) Enbrel, Johnson & Johnson’s (JNJ) Stelara, and Celgene’s (CELG) Otezla in the immunology and inflammation space, AbbVie’s (ABBV) Humira has been the most prescribed biologic therapy in 1Q17.

Humira has maintained its market-leading position in the rheumatology space in 1Q17. The drug also witnessed double-digit growth in prescriptions from the gastrointestinal space in 1Q17. Approximately 50% of the new Crohn’s disease and ulcerative colitis patients have opted for Humira. 

The drug also saw double-digit growth in sales volumes arising from prescriptions in the dermatology space due to increasing use of Humira for treating patients with psoriasis and moderate to severe hidradenitis suppurativa (or HS).

Article continues below advertisement

Revenue performance

In 1Q17, Humira reported global revenues of around $4.1 billion, which is year-over-year (or YoY) operational growth of ~15.8%. The drug earned revenues of ~$2.7 billion in the US market, a 22.8% rise on a YoY basis. This increase was driven by 12% YoY growth in prescription volumes and a rise in drug prices. The drug earned around $1.4 billion from international markets, which equals YoY operational growth of around 4.6%.

Despite increasing competition from branded drugs as well as biosimilars in European markets, AbbVie is confident that Humira’s fiscal 2017 operational revenues could be higher by mid-single digits on YoY basis.

AbbVie makes up about 0.51% of Vanguard S&P 500 ETF’s (VOO) total portfolio holdings.

In the next article, we’ll analyze the growth prospects of AbbVie’s leading oncology drug, Imbruvica, in greater detail.

Advertisement

More From Market Realist